

Date: February 12, 2021

To
The Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Scrip Code: BSE: 526301

Dear Sir,

Sub: Submission of Un-Audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months Period ended 31st December, 2020

In compliance with Regulation 33 & 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the enclosed Un-Audited Financial Results for the Third Quarter and Nine Months Period ended 31st December, 2020 (Standalone and Consolidated) which have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 12, 2021 and also the Limited Review Report furnished by the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company commenced at 1.00 P.M. and concluded at 2.00 P.M.

We request you to please take the above on record.

Thanking you,

Yours faithfully
For Medinova Diagnostic Services Limited


V. Sri Lakshmi
Company Secretary
FCS: 9950

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

(Rs. in Lakhs)

SL No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1	Income:						
	(a) Revenue from operations	336.12	436.44	135.13	904.52	414.75	549.30
	(b) Other Income	8.32	5.52	5.61	19.72	14.32	26.32
	Total Income	344.44	441.96	140.74	924.24	429.07	575.62
2	Expenses						
	(a) Cost of Material Consumed	51.20	38.29	19.60	103.23	65.52	85.55
	(b) Employees benefit Expense	42.39	41.75	44.01	119.68	134.90	178.91
	(c) Testing Fees	84.88	204.12	6.59	310.39	24.00	31.08
	(d) Finance Costs	4.47	9.50	10.60	23.46	32.52	42.36
	(e) Depreciation & Amortisation Expenses	8.61	7.86	10.37	23.69	30.96	41.22
	(f) Other Expenses	62.29	62.44	47.79	168.18	173.40	223.49
	Total Expenses	253.84	363.96	138.96	748.63	461.30	602.61
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	90.61	78.00	1.78	175.62	(32.23)	(26.99)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before Extraordinary items and Tax (3+4)	90.61	78.00	1.78	175.62	(32.23)	(26.99)
6	Extraordinary Items	-	-	-	-	-	-
7	Profit / (Loss) before Tax (5-6)	90.61	78.00	1.78	175.62	(32.23)	(26.99)
8	Tax Expenses						
	(a) Current Tax	1.44	-	-	1.44	-	-
	(b) Deferred Tax (Credit) /Charge	-	-	-	-	-	2.58
	(c) Taxes of earlier years	-	0.43	-	0.43	-	-
9	Profit / (Loss) for the period (7-8)	89.17	77.57	1.78	173.75	(32.23)	(29.57)
10	Other Comprehensive income	-	-	-	-	-	(0.27)
11	Total Comprehensive income for the period (9+10)	89.17	77.57	1.78	173.75	(32.23)	(29.84)
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	(995.68)	995.68	995.68	995.68	995.68	995.68
13	Earnings per Equity Share						
	a) Basic (Rs.)	0.90	0.78	0.02	1.75	(0.32)	(0.30)
	b) Diluted (Rs.)	0.90	0.78	0.02	1.75	(0.32)	(0.30)

Notes to Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2020

1. The unaudited Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th February, 2021. The Statutory Auditors of the Company have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

3. As the Company's business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) " Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.

4. The Company has considered internal and external sources of information up to the date of approval of these financial results in evaluating the possible affects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade and unbilled receivables. The Company has applied prudence in arriving at the estimates and assumptions. The Company is confident about the recoverability of these assets.

5. Previous period Figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable.

For MEDINOVA DIAGNOSTICS SERVICES LTD

Place: Hyderabad
Date: 12.02.2021



SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR

DIN-01409332





Limited Review Report on Unaudited Quarterly Standalone Financial Results of Medinova Diagnostic Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Limited Review Report on Unaudited Standalone Financial Results

**To
The Board of Directors of
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited ("the company") for the Quarter ended 31st December 2020, ("the Statement").
2. The Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 14th August 2019. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognised accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Regd No 006677S



C V Ratnam Dhaveji
Partner, M. No 203479
Hyderabad
12.02.2021
UDIN: 21203479AAAAAG8227

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

(Rs in Lakhs)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1	Income:						
	(a) Revenue from operations	378.13	465.13	183.59	997.50	565.63	744.70
	(b) Other Income	5.30	0.05	0.57	5.75	0.88	7.40
	Total Income	383.43	465.18	184.16	1003.25	566.51	752.10
2	Expenses						
	(a) Cost of Material Consumed	54.46	41.75	22.37	112.21	76.31	108.84
	(b) Employees benefit Expense	45.98	45.56	47.18	130.26	144.22	191.82
	(c) Testing Fees	84.77	204.11	6.59	310.27	24.00	31.08
	(d) Finance Costs	8.42	13.23	14.67	34.81	45.88	59.37
	(e) Depreciation & Amortisation Expenses	18.55	17.80	24.19	53.41	71.52	95.11
	(f) Other Expenses	83.37	83.83	65.59	228.57	234.60	293.45
	Total Expenses	295.55	406.28	180.59	869.53	596.53	779.67
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	87.88	58.90	3.57	133.72	(30.02)	(27.57)
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) before Extraordinary items and Tax (3+4)	87.88	58.90	3.57	133.72	(30.02)	(27.57)
6	Extraordinary Items	-	-	-	-	-	-
7	Profit / (Loss) before Tax (5-6)	87.88	58.90	3.57	133.72	(30.02)	(27.57)
8	Tax Expenses						
	(a) Current Tax	1.44	-	-	1.44	-	-
	(b) Deferred Tax (Credit) / Charge	-	-	-	-	-	(4.80)
	(c) Taxes of earlier years	-	0.43	-	0.43	-	-
9	Profit / (Loss) for the period (7-8)	86.45	58.47	3.57	131.86	(30.02)	(22.77)
10	Other Comprehensive Income	-	-	-	-	-	(0.27)
11	Total Comprehensive income for the period (9+10)	86.45	58.47	3.57	131.86	(30.02)	(23.04)
	Net Profit attributable to:						
	(a) Owners of the Company	87.67	67.07	2.76	150.69	(31.01)	(25.82)
	(b) Non Controlling Interest	(1.22)	(8.60)	0.81	(18.85)	0.99	3.05
	Other Comprehensive Income attributable to:						
	(a) Owners of the Company	-	-	-	-	-	(0.27)
	(b) Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to:						
	(a) Owners of the Company	87.67	67.07	2.76	150.69	(31.01)	(26.09)
	(b) Non Controlling Interest	(1.22)	(8.60)	0.81	(18.85)	0.99	3.05
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
13	Earnings per Equity Share						
	a) Basic (Rs.)	0.88	0.67	0.03	1.51	(0.31)	(0.26)
	b) Diluted (Rs.)	0.88	0.67	0.03	1.51	(0.31)	(0.26)

Notes to Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2020

1. The Consolidated unaudited Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2. The above Consolidated unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th February, 2021. The Statutory Auditors of the Group have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

3. As the Group's business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) "Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.

4. The Group has considered internal and external sources of information up to the date of approval of these financial results in evaluating the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade and unbilled receivables. The Group has applied prudence in arriving at the estimates and assumptions. The Group is confident about the recoverability of these assets.

5. Previous period Figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable.


For MEDINOVA DIAGNOSTICS SERVICES LTD

Place: Hyderabad
Date: 12.02.2021



SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR

DIN 01409332



Limited Audit Report on Unaudited Quarterly Consolidated Financial Results of Medinova Diagnostic Services Limited Under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Limited Review Report on Unaudited Consolidated Financial Results

**To
The Board of Directors,
Medinova Diagnostic Services Limited,
Hyderabad**

1. We have reviewed the accompanying statement of unaudited Consolidated financial results of Medinova Diagnostic Services Limited ("the Parent") and its subsidiary LLP (together referred to as the "Group") for the Quarter ended 31st December 2020, ("the Statements") being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. The Statement, which is the responsibility of the Parents management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Standard 34, Interim Financial Reporting (Ins AS 34) Prescribe under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an Audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable

4. The Statement includes the results of the following entities:

S.No	Name of the Entity	Nature of Relation
1.	Medinova Diagnostics Services Limited	The Parent
2.	Medinova Millennium MRI Services LLP	The Subsidiary LLP



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 as amended with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Regd No 006677S



C V Ratnam Dhaveji
Partner,
M.No 203479
Hyderabad
12.02.2021
UDIN: 21203479AAAAAH9899